NCT04673591 (Tregulaire) is a Phase 2 clinical trial of Tregalizumab in Allergy to House Dust Mite, sponsored by T-Balance Therapeutics GmbH.

Who is sponsoring NCT04673591?

NCT04673591 is sponsored by T-Balance Therapeutics GmbH.

What drugs are being tested in NCT04673591?

Interventions in NCT04673591: Tregalizumab, Placebo.

What condition does NCT04673591 study?

NCT04673591 studies Allergy to House Dust Mite, Allergic Asthma.

Is NCT04673591 still recruiting?

NCT04673591 is currently completed. Last updated 8 February 2022.

Last reviewed 2022-02-08 · How we verify

NCT04673591: Tregulaire

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients

Completed Phase 2 Last updated 8 February 2022

What this trial tests

Phase 2 trial testing Tregalizumab in Allergy to House Dust Mite in 42 participants. Completed in 12 January 2022.

Timeline

9 December 2020

Primary endpoint
12 January 2022

12 January 2022

Quick facts

Lead sponsor	T-Balance Therapeutics GmbH
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	42
Start date	9 December 2020
Primary completion	12 January 2022
Estimated completion	12 January 2022
Sites	1 location across Germany

Drugs / interventions tested

Tregalizumab — full drug profile →
Placebo

Conditions studied

Allergy to House Dust Mite — all drugs for Allergy to House Dust Mite →
Allergic Asthma — all drugs for Allergic Asthma →

Sponsor

T-Balance Therapeutics GmbH

Who can join

Adults 18 to 65, any sex, with Allergy to House Dust Mite or Allergic Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Regulation of Eosinophilia in Asthma-New Therapeutic Approaches for Asthma Treatment.
Cusack RP, Whetstone CE, Xie Y, Ranjbar M, et al · · 2021 · cited 22× · PMID 33917396 · DOI 10.3390/cells10040817

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04673591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by T-Balance Therapeutics GmbH
Last refreshed: 8 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing